Antabio

Executive Summary

Antabio is a private clinical-stage biopharmaceutical company headquartered in Labège, France, dedicated to developing novel antibacterial resistance-breakers to combat severe, drug-resistant infections. The company focuses on multidrug-resistant Gram-negative bacteria that have been identified as critical priorities by both the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC). Its lead program is a next-generation β-lactam/β-lactamase inhibitor combination designed to overcome common resistance mechanisms in life-threatening hospital-acquired infections. With antimicrobial resistance posing a growing global health crisis, Antabio's innovative approach addresses a significant unmet medical need, offering potential solutions against pathogens for which treatment options are increasingly limited. The company was founded in 2007 and has advanced its lead candidate into Phase 1 clinical development. Antabio's strategy leverages its expertise in β-lactamase inhibitor design to restore the efficacy of existing β-lactam antibiotics. As a private entity, the company operates with a focused pipeline aimed at bringing novel therapies to patients. Upcoming catalysts include potential Phase 1 data readouts and updates on its clinical program. The company's success could position it as a key player in the antimicrobial resistance space, though further financing and partnerships will be critical to advancing its pipeline through later-stage trials and regulatory approval.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 clinical data readout for lead β-lactam/β-lactamase inhibitor combination60% success
• H1 2027Announcement of a strategic partnership or licensing deal for development and commercialization40% success
• Q2 2026Presentation of preclinical or Phase 1 data at a major infectious disease conference (e.g., ECCMID, IDWeek)70% success